The Russian pharmaceutical industry is booming, despite the economic recession in the country and devaluation of national currency, caused by sanctions, according to Sergey Tsyb, Russia’s Deputy Minister of Industry and Trade.
According to Mr Tsyb, despite the sanctions, no Russian and Western companies have abandoned their investment plans for Russia for the coming years, reports The Pharma Letter’s Russia correspondent.
Mr Tsyb has explained that the current boom is mainly due to successful implementation of the existing state strategy “Of the development of Russian pharmaceutical industry until 2020,” which resulted in the establishment of production of up to 60% of drugs from the list of vital within the country.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze